David Oyer, MD
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1134226467
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $76,197 of the $101,263 with a category attached, or 75.2%. Novo Nordisk accounts for 65.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $57,008 and has fallen 99.0% since, to $567 in 2025. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 277 payments — averaging $365.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$67K
- Johnson & Johnson$32K
- Bayer$1K
- Mannkind Corporation$294
- Corcept Therapeutics$139
- Regeneron$135
- plus $515 from 12 others
What the payments were for
- Consulting fees$11,19811%
- Speaking & faculty fees$76,19775%
- Travel & lodging$7,6328%
- Food & beverage$4,7805%
- Education$1,4551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 189 | $66,585 |
| Johnson & Johnson | 50 | $32,352 |
| Bayer | 8 | $1,242 |
| Mannkind Corporation | 8 | $294 |
| Corcept Therapeutics | 2 | $139 |
| Regeneron | 2 | $135 |
| Senseonics, Incorporated | 1 | $124 |
| Exact Sciences | 3 | $79 |
| Pfizer | 2 | $53 |
| Amgen | 3 | $51 |
| Insulet Corporation | 2 | $47 |
| AstraZeneca | 1 | $33 |
| GSK | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Abbott | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$101,263 in reported general payments places this provider in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 231 | $369,427 |
| JardianceEmpagliflozin | 110 | $131,547 |
| MounjaroTirzepatide | 79 | $122,546 |
| EliquisApixaban | 73 | $86,382 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $63,191 |
| FarxigaDapagliflozin Propanediol | 22 | $35,801 |
| Tresiba Flextouch U-100Insulin Degludec | 82 | $34,627 |
| KerendiaFinerenone | 21 | $28,961 |
| XareltoRivaroxaban | 64 | $21,203 |
| InvokanaCanagliflozin | 12 | $20,150 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $19,504 |
| Repatha SureclickEvolocumab | 22 | $18,857 |
| LinzessLinaclotide | 25 | $18,440 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $17,035 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $15,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $66,585 | $369,427231 claims |
| Boehringer IngelheimJardiance | $19 | $131,547110 claims |
| Lilly USA, LLCMounjaro, Humalog | $20 | $127,509102 claims |
| PfizerEliquis, Premarin, Paxlovid | $53 | $94,836100 claims |
| Johnson & JohnsonXarelto, Invokana | $32,352 | $41,35376 claims |
| AstraZenecaFarxiga | $33 | $35,80122 claims |
| BayerKerendia | $1,242 | $28,96121 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $25 | $25,94524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- George BakrisChicago$403K
- Wenyu HuangChicago$341K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Tamara VokesChicago$139K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- Hong LeeChicago$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.